Date: 2016-09-20
Type of information: Nomination
Compound:
Company: Aegerion Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 20, 2016, Aegerion Pharmaceuticals announced the appointment of Remi A. Menes as chief commercial officer, effective immediately.Remi Menes most recently served as the General Manager of AbbVie Finland, where he was responsible for the Affiliate's operations and P&L and its flagship product Humira. He also served as Board Member of Pharma Industry Finland. Before joining AbbVie Finland in 2013, Mr. Menes served as Area Commercial Director, Virology & Neonatal Care, Western Europe & Canada at AbbVie Europe. From 2008-2010, he was the Commercial Director, Specialty Products Division and a Member of the Affiliate Leadership Team at Abbott Canada. Between 1990 and 2008, Mr. Menes held a series of roles of increasing responsibility at Merck Frosst Canada Ltd., including Director, Sales & Marketing, in which he led the Canadian launch of Singulair® for Allergic Rhinitis, and Product Manager for Singulair® and Propecia®/Proscar®. He holds an Executive M.B.A. and a B.Sc. in Organic Chemistry with a minor in Business Studies from Concordia University. Aegerion is currently preparing to submit a marketing authorization application for Myalept® in the EU by year-end and, upon anticipated marketing approval, to launch Juxtapid® in Japan.
Financial terms:
Latest news:
